C07K 14/7151
For tumor necrosis factor [tnf], for lymphotoxin [lt]
Official title: {for tumor necrosis factor [TNF], for lymphotoxin [LT]}
C07K14/7151 (For tumor necrosis factor [tnf], for lymphotoxin [lt]) appears on 532 US grants and 760 published applications in this corpus.
Search patents in C07K- Granted patents
- 532
- Published applications
- 760
- Assignees
- 299
- Inventors
- 1,134
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 2 | 0 |
| 1995 | 4 | 0 |
| 1996 | 7 | 0 |
| 1997 | 9 | 0 |
| 1998 | 15 | 0 |
| 1999 | 19 | 0 |
| 2000 | 9 | 0 |
| 2001 | 15 | 3 |
| 2002 | 22 | 45 |
| 2003 | 25 | 49 |
| 2004 | 8 | 28 |
| 2005 | 15 | 30 |
| 2006 | 20 | 27 |
| 2007 | 25 | 37 |
| 2008 | 16 | 27 |
| 2009 | 16 | 25 |
| 2010 | 30 | 27 |
| 2011 | 10 | 26 |
| 2012 | 18 | 23 |
| 2013 | 16 | 33 |
| 2014 | 15 | 30 |
| 2015 | 15 | 30 |
| 2016 | 20 | 34 |
| 2017 | 23 | 26 |
| 2018 | 17 | 41 |
| 2019 | 18 | 35 |
| 2020 | 26 | 25 |
| 2021 | 24 | 29 |
| 2022 | 18 | 37 |
| 2023 | 7 | 27 |
| 2024 | 13 | 27 |
| 2025 | 20 | 17 |
| 2026 | 14 | 22 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Process for producing donor-batched cells expressing a recombinant receptor11 Aug 2026US 12,703,733 B2Juno Therapeutics, Inc.
- Methods for making stable protein compositions14 Jul 2026US 12,679,865 B2Amgen Inc.
- Heterodimeric human IgG1 polypeptides with isoelectric point modifications23 Jun 2026US 12,662,553 B2Xencor, Inc.
- Method for diagnosing human T-cell leukemia virus type 1 (HTLV-1)-related disease16 Jun 2026US 12,656,345 B2NEC Corporation
- Heterodimeric human IgG1 polypeptides with isoelectric point modifications5 May 2026US 12,617,872 B2Xencor, Inc.
- Chimeric antigen receptors including jak/stat binding domains and modified immune cells10 Sep 2026US 2026/0265337 A1Carisma Therapeutics Inc.
- Novel fusion protein for treating autoimmune diseases10 Sep 2026US 2026/0265340 A1Curogen Technology Co., Ltd.
- Engineered Expression of Cell Surface and Secreted Sialidase by CAR T Cells for Increased Efficacy in Solid Tumors3 Sep 2026US 2026/0258355 A1The Trustees of the University of Pennsylvania
- Anti-Human Transferrin Receptor Antibody Permeating Blood-Brain Barrier2 Jul 2026US 2026/0184781 A1JCR Pharmaceuticals Co., Ltd.
- Chimeric Receptors to STEAP1 and Methods Of Use Thereof2 Jul 2026US 2026/0184816 A1Amgen Inc.
Most cited
By later US patents
- Methods of lowering active TNF-.alpha. levels in mammals using tumor necrosis factor receptor301US 5,605,690 AImmunex Corporation · 1997
- DNA encoding a chimeric polypeptide comprising the extracellular domain of TNF receptor fused to IgG, vectors, and host cells271US 5,447,851 ABoard of Regents, The University of Texas System · 1995
- Albumin fusion proteins comprising GLP-1 polypeptides198US 7,141,547 B2Human Genome Sciences, Inc. · 2006
- Fc variants with altered binding to FcRn193US 8,367,805 B2Xencor, Inc. · 2013
- Albumin fusion proteins157US 6,905,688 B2Human Genome Sciences, Inc. · 2005